| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP17A1 |
| Uniprot No | P05093 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-508aa |
| 氨基酸序列 | MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST |
| 预测分子量 | 84.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CYP17A1重组蛋白的假设参考文献(内容基于典型研究方向构建，非真实文献)：
1. **《Structural characterization of human CYP17A1 in complex with abiraterone》**
*作者：Johnson, R.W. et al.*
摘要：通过X射线晶体学解析了人源CYP17A1重组蛋白与前列腺癌药物阿比特龙的复合物结构，揭示了其底物结合口袋的构象变化及药物抑制机制。
2. **《Functional expression of recombinant CYP17A1 in E. coli for steroidogenesis studies》**
*作者：Zhang, L. & Wang, H.*
摘要：报道了一种在大肠杆菌中高效表达可溶性CYP17A1重组蛋白的方法，验证其催化孕烯醇酮向17-羟基孕烯醇酮转化的活性，用于体外类固醇合成通路研究。
3. **《Role of CYP17A1 cytochrome b5 interactions in androgen biosynthesis》**
*作者：Miller, K.K. et al.*
摘要：利用重组人CYP17A1蛋白和细胞色素b5共表达系统，证明b5通过增强17.20-裂解酶活性调节雄激素合成效率，为先天性肾上腺增生症机制提供新见解。
4. **《Inhibitor screening platform using fluorescent-based CYP17A1 activity assay》**
*作者：Sato, T. et al.*
摘要：开发基于重组CYP17A1蛋白的高通量荧光检测法，筛选新型抑制剂并评估其对17α-羟化酶和17.20-裂解酶双功能活性的选择性抑制作用。
CYP17A1 (cytochrome P450 family 17 subfamily A member 1) is a critical enzyme in steroid biosynthesis, primarily expressed in the adrenal glands and gonads. It catalyzes two sequential reactions: the 17α-hydroxylation of pregnenolone/progesterone to form 17α-hydroxypregnenolone/17α-hydroxyprogesterone, followed by the cleavage of the C17–20 bond (lyase activity) to produce dehydroepiandrosterone (DHEA) and androstenedione, precursors of sex hormones. This dual functionality makes CYP17A1 a key regulator of glucocorticoid and androgen/estrogen synthesis, linking the production of cortisol and sex steroids.
Dysregulation of CYP17A1 is implicated in disorders like congenital adrenal hyperplasia, polycystic ovary syndrome (PCOS), and hormone-dependent cancers (e.g., prostate cancer). Its pivotal role in androgen synthesis has made it a therapeutic target, with inhibitors like abiraterone acetate used clinically to suppress androgen production in prostate cancer.
Recombinant CYP17A1 protein is produced using heterologous expression systems (e.g., E. coli, yeast, or mammalian cells) to study its structure, enzymatic mechanisms, and interactions with drugs or inhibitors. Engineered variants often include modifications to enhance solubility, stability, or catalytic efficiency. Co-expression with redox partner proteins (e.g., cytochrome P450 reductase) is sometimes required to reconstitute activity in vitro.
Research using recombinant CYP17A1 has advanced understanding of its substrate specificity, reaction kinetics, and inhibition profiles. Structural studies (X-ray crystallography/cryo-EM) have revealed substrate-binding pockets and mechanisms underlying its dual enzymatic activities. This knowledge drives the development of selective inhibitors and modulators for precision therapies. Additionally, recombinant CYP17A1 serves as a tool for high-throughput drug screening and biomarker analysis in endocrine disorders.
×
